Collagenous Colitis Clinical Trial
Official title:
Rifaximin-treatment of Collagenous Colitis:
The hypothesis of this study is that an altered gut microbiota is a contributory factor in initiating an inflammatory process in the colonic mucosa leading to collagenous colitis. The investigators suggest that treatment with budesonide reduces the inflammation without treating the underlying cause. In this trial the investigators will try to modullate gut microbiota by adding rifaximin. The aim of this study is to assess if 4 weeks treatment with rifaximin as a supplement to a standard course of budesonide against active CC can reduce the risk of relapse after treatment cessation.
Patients with biopsy-verified CC and active disease defined by >3 bowel movements/day or >1 watery stool measured as a mean for a week. Patients will be invited to participate in the study independently of age and disease duration. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00139165 -
Long-Term Treatment of Collagenous Colitis With Budesonide
|
Phase 3 | |
| Completed |
NCT00450086 -
Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis
|
Phase 3 | |
| Recruiting |
NCT01504048 -
Usefulness of Chromoendoscopy in Diagnosing Microscopic Colitis
|
N/A | |
| Completed |
NCT01928667 -
Case-Control Study to Identify Risk Factors for Microscopic Colitis
|
N/A | |
| Completed |
NCT00180076 -
Budesonide for Maintenance Treatment of Collagenous Colitis
|
Phase 3 |